Compare LyondellBasell Industries NV (LYB) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LyondellBasell Industries NV vs GeneDx Holdings Corp — how do they compare? LyondellBasell Industries NV trades at $61.25 (market cap $19.60B), while GeneDx Holdings Corp trades at $61.92 (market cap $1.80B). The key difference: LyondellBasell Industries NV is far larger — about 10.9× GeneDx Holdings Corp's market cap, and LyondellBasell Industries NV pays a 6.78% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| LYB | WGS | |
|---|---|---|
Market Cap | $19.60B | $1.80B |
Sector | Basic Materials | Technology |
52-Week High | $82.38 | $167.51 |
52-Week Low | $42.28 | $34.51 |
Enterprise Value | $31.22B | $1.80B |
Dividend Yield | 6.78% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LyondellBasell (LYB) trades at $61.19, up 3.38% today, with a bullish technical signal and strong analyst consensus price target of $72.56. Recent earnings show volatility with Q1 2026 beating expectations, while Q4 2025 missed. The company maintains positive cash flow and recently announced a $0.69 dividend. Revenue has declined from $50.5B in 2022 to $30.2B in 2025, with net income turning negative at -$745M. News highlights include partnerships for sustainable packaging and anticipation of strong Q2 2026 earnings.
LYB presents a mixed outlook: potential upside exists from expected earnings recovery and strategic shifts toward high-margin polymers, but risks include declining revenue, negative profitability, and high debt. Investors should weigh the bullish analyst sentiment against fundamental challenges in the chemical sector.
GeneDx Holdings (WGS) trades at $60.65, down 4.46% today, amid a bearish technical signal and multiple class-action lawsuits alleging securities fraud. The stock shows weak fundamentals with a negative net income margin of -17.58% and ROE of -30.42%, though it beat EPS estimates in two of the last three quarters. Revenue grew to $427.54M in 2025 but profitability remains a challenge, with a high EV/EBITDA of 161.17 indicating stretched valuation relative to earnings.
Despite a 90.9% analyst buy rating and a $75.40 consensus price target, significant risks from litigation and persistent losses cloud the outlook. The stock faces near-term pressure from legal overhangs, while operational cash flow turned negative in 2026. Investors should weigh high analyst optimism against substantial fundamental and legal headwinds before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About LyondellBasell Industries NV
LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
